Search

Your search keyword '"Christian T. Happi"' showing total 8 results
Start Over Author "Christian T. Happi" Journal nature communications
8 results on '"Christian T. Happi"'

1. Metagenomic surveillance uncovers diverse and novel viral taxa in febrile patients from Nigeria

Author

Judith U. Oguzie, Brittany A. Petros, Paul E. Oluniyi, Samar B. Mehta, Philomena E. Eromon, Parvathy Nair, Opeoluwa Adewale-Fasoro, Peace Damilola Ifoga, Ikponmwosa Odia, Andrzej Pastusiak, Otitoola Shobi Gbemisola, John Oke Aiyepada, Eghosasere Anthonia Uyigue, Akhilomen Patience Edamhande, Osiemi Blessing, Michael Airende, Christopher Tomkins-Tinch, James Qu, Liam Stenson, Stephen F. Schaffner, Nicholas Oyejide, Nnenna A. Ajayi, Kingsley Ojide, Onwe Ogah, Chukwuyem Abejegah, Nelson Adedosu, Oluwafemi Ayodeji, Ahmed A. Liasu, Sylvanus Okogbenin, Peter O. Okokhere, Daniel J. Park, Onikepe A. Folarin, Isaac Komolafe, Chikwe Ihekweazu, Simon D. W. Frost, Ethan K. Jackson, Katherine J. Siddle, Pardis C. Sabeti, and Christian T. Happi

Subjects
Science
Abstract

Abstract Effective infectious disease surveillance in high-risk regions is critical for clinical care and pandemic preemption; however, few clinical diagnostics are available for the wide range of potential human pathogens. Here, we conduct unbiased metagenomic sequencing of 593 samples from febrile Nigerian patients collected in three settings: i) population-level surveillance of individuals presenting with symptoms consistent with Lassa Fever (LF); ii) real-time investigations of outbreaks with suspected infectious etiologies; and iii) undiagnosed clinically challenging cases. We identify 13 distinct viruses, including the second and third documented cases of human blood-associated dicistrovirus, and a highly divergent, unclassified dicistrovirus that we name human blood-associated dicistrovirus 2. We show that pegivirus C is a common co-infection in individuals with LF and is associated with lower Lassa viral loads and favorable outcomes. We help uncover the causes of three outbreaks as yellow fever virus, monkeypox virus, and a noninfectious cause, the latter ultimately determined to be pesticide poisoning. We demonstrate that a local, Nigerian-driven metagenomics response to complex public health scenarios generates accurate, real-time differential diagnoses, yielding insights that inform policy.

Published
2023
Full Text
View/download PDF

2. Emergence and spread of two SARS-CoV-2 variants of interest in Nigeria

Author

Idowu B. Olawoye, Paul E. Oluniyi, Judith U. Oguzie, Jessica N. Uwanibe, Tolulope A. Kayode, Testimony J. Olumade, Fehintola V. Ajogbasile, Edyth Parker, Philomena E. Eromon, Priscilla Abechi, Tope A. Sobajo, Chinedu A. Ugwu, Uwem E. George, Femi Ayoade, Kazeem Akano, Nicholas E. Oyejide, Iguosadolo Nosamiefan, Iyanuoluwa Fred-Akintunwa, Kemi Adedotun-Sulaiman, Farida B. Brimmo, Babatunde B. Adegboyega, Courage Philip, Richard A. Adeleke, Grace C. Chukwu, Muhammad I. Ahmed, Oludayo O. Ope-Ewe, Shobi G. Otitoola, Olusola A. Ogunsanya, Mudasiru F. Saibu, Ayotunde E. Sijuwola, Grace O. Ezekiel, Oluwagboadurami G. John, Julie O. Akin-John, Oluwasemilogo O. Akinlo, Olanrewaju O. Fayemi, Testimony O. Ipaye, Deborah C. Nwodo, Abolade E. Omoniyi, Iyobosa B. Omwanghe, Christabel A. Terkuma, Johnson Okolie, Olubukola Ayo-Ale, Odia Ikponmwosa, Ebo Benevolence, Grace O. Naregose, Akhilomen E. Patience, Osiemi Blessing, Airende Micheal, Agbukor Jacqueline, John O. Aiyepada, Paulson Ebhodaghe, Omiunu Racheal, Esumeh Rita, Giwa E. Rosemary, Ehikhametalor Solomon, Ekanem Anieno, Yerumoh Edna, Aire O. Chris, Adomeh I. Donatus, Ephraim Ogbaini-Emovon, Mirabeau Y. Tatfeng, Hannah E. Omunakwe, Mienye Bob-Manuel, Rahaman A. Ahmed, Chika K. Onwuamah, Joseph O. Shaibu, Azuka Okwuraiwe, Anthony E. Ataga, Andrew Bock-Oruma, Funmi Daramola, Ibrahim F. Yusuf, Akinwumi Fajola, Nsikak-Abasi Ntia, Julie J. Ekpo, Anietie E. Moses, Beatrice W. Moore-Igwe, Oluwatosin E. Fakayode, Monilade Akinola, Ibrahim M. Kida, Bamidele S. Oderinde, Zara W. Wudiri, Oluwapelumi O. Adeyemi, Olusola A. Akanbi, Anthony Ahumibe, Afolabi Akinpelu, Oyeronke Ayansola, Olajumoke Babatunde, Adesuyi A. Omoare, Chimaobi Chukwu, Nwando G. Mba, Ewean C. Omoruyi, Olasunkanmi Olisa, Olatunji K. Akande, Ifeanyi E. Nwafor, Matthew A. Ekeh, Erim Ndoma, Richard L. Ewah, Rosemary O. Duruihuoma, Augustine Abu, Elizabeth Odeh, Venatius Onyia, Chiedozie K. Ojide, Sylvanus Okoro, Daniel Igwe, Emeka O. Ogah, Kamran Khan, Nnennaya A. Ajayi, Collins N. Ugwu, Kingsley N. Ukwaja, Ngozi I. Ugwu, Chukwuyem Abejegah, Nelson Adedosu, Olufemi Ayodeji, Ahmed A. Liasu, Rafiu O. Isamotu, Galadima Gadzama, Brittany A. Petros, Katherine J. Siddle, Stephen F. Schaffner, George Akpede, Cyril Oshomah Erameh, Marycelin M. Baba, Femi Oladiji, Rosemary Audu, Nnaemeka Ndodo, Adeola Fowotade, Sylvanus Okogbenin, Peter O. Okokhere, Danny J. Park, Bronwyn L. Mcannis, Ifedayo M. Adetifa, Chikwe Ihekweazu, Babatunde L. Salako, Oyewale Tomori, Anise N. Happi, Onikepe A. Folarin, Kristian G. Andersen, Pardis C. Sabeti, and Christian T. Happi

Subjects
Science
Abstract

Data on geographically restricted SARS-CoV-2 variants is lacking in some regions. In this nationwide effort including 18 public health labs, the authors used genomic epidemiology and travel data to understand the origin and spread of 2 variants of interest that predominated during the second wave of the pandemic in Nigeria.

Published
2023
Full Text
View/download PDF

3. Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2

Author

Jon Arizti-Sanz, Catherine A. Freije, Alexandra C. Stanton, Brittany A. Petros, Chloe K. Boehm, Sameed Siddiqui, Bennett M. Shaw, Gordon Adams, Tinna-Solveig F. Kosoko-Thoroddsen, Molly E. Kemball, Jessica N. Uwanibe, Fehintola V. Ajogbasile, Philomena E. Eromon, Robin Gross, Loni Wronka, Katie Caviness, Lisa E. Hensley, Nicholas H. Bergman, Bronwyn L. MacInnis, Christian T. Happi, Jacob E. Lemieux, Pardis C. Sabeti, and Cameron Myhrvold

Subjects
Science
Abstract

The COVID-19 pandemic has highlighted the need for user-friendly diagnostic techniques. Here, the authors present SHINE, a streamlined and optimised Cas13-based method with accompanying smartphone app for visual diagnosis.

Published
2020
Full Text
View/download PDF

4. Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time

Author

Kayla G. Barnes, Anna E. Lachenauer, Adam Nitido, Sameed Siddiqui, Robin Gross, Brett Beitzel, Katherine J. Siddle, Catherine A. Freije, Bonnie Dighero-Kemp, Samar B. Mehta, Amber Carter, Jessica Uwanibe, Fehintola Ajogbasile, Testimony Olumade, Ikponmwosa Odia, John Demby Sandi, Mambu Momoh, Hayden C. Metsky, Chloe K. Boehm, Aaron E. Lin, Molly Kemball, Daniel J. Park, Luis Branco, Matt Boisen, Brian Sullivan, Mihret F. Amare, Abdulwasiu B. Tiamiyu, Zahra F. Parker, Michael Iroezindu, Donald S. Grant, Kayvon Modjarrad, Cameron Myhrvold, Robert F. Garry, Gustavo Palacios, Lisa E. Hensley, Stephen F. Schaffner, Christian T. Happi, Andres Colubri, and Pardis C. Sabeti

Subjects
Science
Abstract

Outbreaks of viral hemorrhagic fevers highlight the need for sensitive, field-deployable diagnostics. Here the authors present a CRISPR-based SHERLOCK platform with field protocol and mobile app for Ebola and Lassa fever outbreaks.

Published
2020
Full Text
View/download PDF

5. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

Author

James E. Robinson, Kathryn M. Hastie, Robert W. Cross, Rachael E. Yenni, Deborah H. Elliott, Julie A. Rouelle, Chandrika B. Kannadka, Ashley A. Smira, Courtney E. Garry, Benjamin T. Bradley, Haini Yu, Jeffrey G. Shaffer, Matt L. Boisen, Jessica N. Hartnett, Michelle A. Zandonatti, Megan M. Rowland, Megan L. Heinrich, Luis Martínez-Sobrido, Benson Cheng, Juan C. de la Torre, Kristian G. Andersen, Augustine Goba, Mambu Momoh, Mohamed Fullah, Michael Gbakie, Lansana Kanneh, Veronica J. Koroma, Richard Fonnie, Simbirie C. Jalloh, Brima Kargbo, Mohamed A. Vandi, Momoh Gbetuwa, Odia Ikponmwosa, Danny A. Asogun, Peter O. Okokhere, Onikepe A. Follarin, John S. Schieffelin, Kelly R. Pitts, Joan B. Geisbert, Peter C. Kulakoski, Russell B. Wilson, Christian T. Happi, Pardis C. Sabeti, Sahr M. Gevao, S. Humarr Khan, Donald S. Grant, Thomas W. Geisbert, Erica Ollmann Saphire, Luis M. Branco, and Robert F. Garry

Subjects
Science
Abstract

Lassa virus can cause haemorrhagic fever for which no specific treatment currently exists. Here the authors have cloned 113 monoclonal antibodies from the survivors of Lassa infection and show that the majority of neutralizing antibodies target a complex of GP1 and GP2 viral proteins.

Published
2016
Full Text
View/download PDF

6. Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2

Author

Christian T. Happi, Alexandra C. Stanton, Sameed Siddiqui, Chloe K. Boehm, Molly Kemball, Nicholas H. Bergman, Bennett M. Shaw, Fehintola V. Ajogbasile, Loni Wronka, Jacob E. Lemieux, Brittany A. Petros, Catherine A. Freije, Cameron Myhrvold, Bronwyn MacInnis, Gordon Adams, Katie Caviness, Lisa E. Hensley, Philomena Eromon, Robin Gross, Tinna Solveig F. Kosoko-Thoroddsen, Pardis C. Sabeti, Jessica N. Uwanibe, and Jon Arizti-Sanz

Subjects
0301 basic medicine, 2019-20 coronavirus outbreak, CRISPR-Cas systems, Coronavirus disease 2019 (COVID-19), Computer science, Science, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), General Physics and Astronomy, Single step, 02 engineering and technology, Computational biology, Smartphone application, General Biochemistry, Genetics and Molecular Biology, Article, 03 medical and health sciences, lcsh:Science, Multidisciplinary, Assay systems, Molecular engineering, Infectious-disease diagnostics, General Chemistry, 021001 nanoscience & nanotechnology, CRISPR-Associated Proteins, 030104 developmental biology, Smartphone app, lcsh:Q, 0210 nano-technology, Disease transmission
Abstract

The COVID-19 pandemic has highlighted that new diagnostic technologies are essential for controlling disease transmission. Here, we develop SHINE (Streamlined Highlighting of Infections to Navigate Epidemics), a sensitive and specific diagnostic tool that can detect SARS-CoV-2 RNA from unextracted samples. We identify the optimal conditions to allow RPA-based amplification and Cas13-based detection to occur in a single step, simplifying assay preparation and reducing run-time. We improve HUDSON to rapidly inactivate viruses in nasopharyngeal swabs and saliva in 10 min. SHINE’s results can be visualized with an in-tube fluorescent readout — reducing contamination risk as amplification reaction tubes remain sealed — and interpreted by a companion smartphone application. We validate SHINE on 50 nasopharyngeal patient samples, demonstrating 90% sensitivity and 100% specificity compared to RT-qPCR with a sample-to-answer time of 50 min. SHINE has the potential to be used outside of hospitals and clinical laboratories, greatly enhancing diagnostic capabilities., The COVID-19 pandemic has highlighted the need for user-friendly diagnostic techniques. Here, the authors present SHINE, a streamlined and optimised Cas13-based method with accompanying smartphone app for visual diagnosis.

Published
2020

7. Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time

Author

Brett Beitzel, Don Grant, Kayla G. Barnes, Mihret F. Amare, Robert F. Garry, Testimony J. Olumade, Christian T. Happi, Aaron E. Lin, Chloe K. Boehm, Michael Iroezindu, Robin Gross, Ikponmwosa Odia, Fehintola V. Ajogbasile, Hayden C. Metsky, Samar B. Mehta, Anna E. Lachenauer, Kayvon Modjarrad, Katherine J. Siddle, Luís C. Branco, Pardis C. Sabeti, Gustavo Palacios, Jessica N. Uwanibe, Sameed Siddiqui, Zahra Parker, Brian M. Sullivan, Abdulwasiu B. Tiamiyu, Lisa E. Hensley, Daniel J. Park, Matthew L. Boisen, Stephen F. Schaffner, Cameron Myhrvold, John Demby Sandi, Mambu Momoh, Catherine A. Freije, Amber Carter, Andrés Colubri, Bonnie Dighero-Kemp, Adam Nitido, and Molly Kemball

Subjects
0301 basic medicine, CRISPR-Cas systems, Science, viruses, General Physics and Astronomy, 02 engineering and technology, Diagnostic tools, medicine.disease_cause, Antibodies, Viral, General Biochemistry, Genetics and Molecular Biology, Article, Sierra leone, 03 medical and health sciences, Lassa Fever, Virology, medicine, CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats, lcsh:Science, Lassa fever, Lassa virus, Multidisciplinary, Ebola virus, business.industry, virus diseases, Outbreak, General Chemistry, Hemorrhagic Fever, Ebola, 021001 nanoscience & nanotechnology, medicine.disease, Ebolavirus, Hemorrhagic Fevers, 030104 developmental biology, Viral infection, lcsh:Q, 0210 nano-technology, business
Abstract

Recent outbreaks of viral hemorrhagic fevers (VHFs), including Ebola virus disease (EVD) and Lassa fever (LF), highlight the urgent need for sensitive, deployable tests to diagnose these devastating human diseases. Here we develop CRISPR-Cas13a-based (SHERLOCK) diagnostics targeting Ebola virus (EBOV) and Lassa virus (LASV), with both fluorescent and lateral flow readouts. We demonstrate on laboratory and clinical samples the sensitivity of these assays and the capacity of the SHERLOCK platform to handle virus-specific diagnostic challenges. We perform safety testing to demonstrate the efficacy of our HUDSON protocol in heat-inactivating VHF viruses before SHERLOCK testing, eliminating the need for an extraction. We develop a user-friendly protocol and mobile application (HandLens) to report results, facilitating SHERLOCK’s use in endemic regions. Finally, we successfully deploy our tests in Sierra Leone and Nigeria in response to recent outbreaks., Outbreaks of viral hemorrhagic fevers highlight the need for sensitive, field-deployable diagnostics. Here the authors present a CRISPR-based SHERLOCK platform with field protocol and mobile app for Ebola and Lassa fever outbreaks.

Published
2020

8. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits

Author

Robert W. Cross, Matthew L. Boisen, Mambu Momoh, Megan L. Heinrich, Michelle Zandonatti, Michael Gbakie, Joan B. Geisbert, Simbirie Jalloh, Juan Carlos de la Torre, Chandrika B. Kannadka, Momoh Gbetuwa, Julie A. Rouelle, Onikepe A. Follarin, S. Humarr Khan, Ashley A. Smira, Mohamed Fullah, Benjamin T. Bradley, Richard Fonnie, Kathryn M. Hastie, Luis M. Branco, Russell B. Wilson, Veronica J. Koroma, Danny Asogun, Mohamed A. Vandi, Christian T. Happi, Megan M. Rowland, Benson Yee Hin Cheng, Robert F. Garry, Deborah H. Elliott, Augustine Goba, Pardis C. Sabeti, Kristian G. Andersen, Brima Kargbo, Jeffrey G. Shaffer, James E. Robinson, Peter C. Kulakoski, Kelly R. Pitts, Thomas W. Geisbert, Luis Martinez-Sobrido, Donald S. Grant, Erica Ollmann Saphire, Peter O Okokhere, Odia Ikponmwosa, Lansana Kanneh, Courtney E Garry, Jessica N. Hartnett, John S. Schieffelin, Rachael E. Yenni, Sahr M. Gevao, and Haini Yu

Subjects
0301 basic medicine, Models, Molecular, medicine.drug_class, viruses, Science, General Physics and Astronomy, Cross Reactions, Monoclonal antibody, medicine.disease_cause, Antibodies, Viral, General Biochemistry, Genetics and Molecular Biology, Epitope, Article, 03 medical and health sciences, Epitopes, Lassa Fever, Viral Envelope Proteins, Glycoprotein complex, Antibody Specificity, medicine, Humans, Lassa fever, Lassa virus, Antigens, Viral, Sequence Deletion, chemistry.chemical_classification, Multidisciplinary, biology, Antibodies, Monoclonal, virus diseases, General Chemistry, Arenavirus, medicine.disease, Virology, Antibodies, Neutralizing, 3. Good health, 030104 developmental biology, Epitope mapping, chemistry, biology.protein, Mutagenesis, Site-Directed, Antibody, Glycoprotein, Epitope Mapping
Abstract

Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been identified or characterized. Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV glycoproteins from memory B cells of Lassa fever survivors from West Africa. One-half bind the GP2 fusion subunit, one-fourth recognize the GP1 receptor-binding subunit and the remaining fourth are specific for the assembled glycoprotein complex, requiring both GP1 and GP2 subunits for recognition. Notably, of the 16 mAbs that neutralize LASV, 13 require the assembled glycoprotein complex for binding, while the remaining 3 require GP1 only. Compared with non-neutralizing mAbs, neutralizing mAbs have higher binding affinities and greater divergence from germline progenitors. Some mAbs potently neutralize all four LASV lineages. These insights from LASV human mAb characterization will guide strategies for immunotherapeutic development and vaccine design., Lassa virus can cause haemorrhagic fever for which no specific treatment currently exists. Here the authors have cloned 113 monoclonal antibodies from the survivors of Lassa infection and show that the majority of neutralizing antibodies target a complex of GP1 and GP2 viral proteins.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results